Surgical pathology of lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 6, 2013, Pages 770-786

  Rezaei, M Katayoon ^a   Nolan, Norris J ^a   Schwartz, Arnold M ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adenocarcinoma; adenoid cystic carcinoma; large cell carcinoma; lung cancer; mesothelioma; mucoepidermoid carcinoma; neuroendocrine carcinoma; small cell carcinoma; squamous cell carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARCINOEMBRYONIC ANTIGEN; CD56 ANTIGEN; CHROMOGRANIN; CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; ELASTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FORMALDEHYDE; GEFITINIB; HEMOSIDERIN; IRON; KERATIN; MELANIN; MUCIN; NAPSIN A; PARAFFIN; PROTEIN P53; PROTEIN P63; RETICULIN; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TISSUE CULTURE MEDIUM; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; BRONCHIOLOALVEOLAR ADENOCARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOID; CELL JUNCTION; CELL NUCLEUS; CELL SHAPE; CELLULAR DISTRIBUTION; CHROMATIN; CONNECTIVE TISSUE; CRYOPRESERVATION; DISTANT METASTASIS; EPITHELIAL MYOEPITHELIAL CARCINOMA; GENE MUTATION; GENE REARRANGEMENT; GOBLET CELL; HISTOCHEMISTRY; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ATYPICAL CARCINOID; LUNG CANCER; LUNG CARCINOMA; LUNG LARGE CELL CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TYPICAL CARCINOID TUMOR; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA EFFUSION; METASTATIC MELANOMA; MICROSCOPY; MITOSIS RATE; MOLECULARLY TARGETED THERAPY; NUCLEOLUS; OVERALL SURVIVAL; PATHOLOGIST; PERINEURAL INVASION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ROSETTE FORMATION; SALIVARY GLAND CANCER; SALIVARY GLAND CARCINOMA; STROMA; SURGICAL PATHOLOGY; SURVIVAL RATE; TISSUE FIXATION; TUMOR DIFFERENTIATION; TUMOR NECROSIS;

ADENOCARCINOMA; ALGORITHMS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM STAGING; PATHOLOGY, SURGICAL; PATIENT CARE TEAM; PATIENT-CENTERED CARE; PLEURAL NEOPLASMS; PROGNOSIS;

EID: 84888376444     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1358558     Document Type: Article

References (117)

1. Cagle P. T., Allen T. C., Dacic S., et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med: 2011; 135 1 110 116
2. Schwartz A. M., Henson D. E.; American College of Chest Physicians. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest: 2007; 132 (3, Suppl): 78S 93S (Pubitemid 47502801)
3. Schwartz A. M., Rezaei M. K. Diagnostic surgical pathology in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest: 2013; 143 (5, Suppl): e251S e262S
4. Travis W. D., Brambilla E., Müller-Hermelink H. K., Harris C. C., Eds. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours, Vol 10. Lyon, France IARC: 2004
5. Travis W. D. Pathology of lung cancer. Clin Chest Med: 2011; 32 4 669 692
6. Travis W. D. Pathology of lung cancer. Clin Chest Med: 2002; 23 1 65 81, viii (Pubitemid 34207764)
7. Chamberlain D. W., Wenckebach G. F., Alexander F., Fraser R. S., Kolin A., Newman T. Pathological examination and the reporting of lung cancer specimens. Clin Lung Cancer: 2000; 1 4 261 268
8. Nana-Sinkam S. P., Powell C. A. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest: 2013; 143 (5, Suppl): e30S e39S
9. Rekhtman N., Ang D. C., Sima C. S., Travis W. D., Moreira A. L. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol: 2011; 24 10 1348 1359
10. Sigel C. S., Moreira A. L., Travis W. D., et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol: 2011; 6 11 1849 1856
11. Thunnissen E., Kerr K. M., Herth F. J., et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer: 2012; 76 1 1 18
12. Hasanovic A., Rekhtman N., Sigel C. S., Moreira A. L. Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma. Pathol Res Int: 2011; 2011 897292
13. Rekhtman N., Brandt S. M., Sigel C. S., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol: 2011; 6 3 451 458
14. Mani H., Zander D. S. Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 1. Chest: 2012; 142 5 1316 1323
15. Mani H., Zander D. S. Immunohistochemistry: applications to the evaluation of lung and pleural neoplasms: part 2. Chest: 2012; 142 5 1324 1333
16. Yang M., Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol: 2010; 23 5 654 661
17. Bishop J. A., Sharma R., Illei P. B. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol: 2010; 41 1 20 25
18. Bordoni A., Bongiovanni M., Mazzucchelli L., Spitale A. Impact of histopathological diagnosis with ancillary immunohistochemical studies on lung cancer subtypes incidence and survival: a population-based study. J Cancer Epidemiol: 2011; 2011 275758 doi:10.1155/2011/275758. Epub 2011 Dec 29
19. Ikeda S., Fujimori M., Shibata S., et al. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer: 2006; 6 31
20. Park S. Y., Kim B. H., Kim J. H., Lee S., Kang G. H. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med: 2007; 131 10 1561 1567 (Pubitemid 47606722)
21. Ordóñez N. G. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol: 2003; 27 8 1031 1051 (Pubitemid 36909525)
22. Kalhor N., Zander D. S., Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol: 2006; 19 8 1117 1123 (Pubitemid 44106727)
23. Mukhopadhyay S., Katzenstein A. L. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol: 2011; 35 1 15 25
24. Ring B. Z., Seitz R. S., Beck R. A., et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol: 2009; 22 8 1032 1043
25. Kargi A., Gurel D., Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol: 2007; 15 4 415 420 (Pubitemid 350307847)
26. Travis W. D., Brambilla E., Noguchi M., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol: 2011; 6 2 244 285
27. Travis W. D., Brambilla E., Van Schil P., et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J: 2011; 38 2 239 243
28. Barletta J. A., Yeap B. Y., Chirieac L. R. Prognostic significance of grading in lung adenocarcinoma. Cancer: 2010; 116 3 659 669
29. Yoshizawa A., Motoi N., Riely G. J., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol: 2011; 24 5 653 664
30. Thunnissen E., Beasley M. B., Borczuk A. C., et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma: an international interobserver study. Mod Pathol: 2012; 25 12 1574 1583
31. Noguchi M., Morikawa A., Kawasaki M., et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer: 1995; 75 12 2844 2852
32. Suzuki K., Yokose T., Yoshida J., et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg: 2000; 69 3 893 897 (Pubitemid 30184718)
33. Van Schil P. E., Asamura H., Rusch V. W., et al. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J: 2012; 39 2 478 486
34. Borczuk A. C. Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Mod Pathol: 2012; 25 01 S1 S10
35. Girard N., Deshpande C., Lau C., et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol: 2009; 33 12 1752 1764
36. Girard N., Ostrovnaya I., Lau C., et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res: 2009; 15 16 5184 5190
37. Terry J., Leung S., Laskin J., Leslie K. O., Gown A. M., Ionescu D. N. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol: 2010; 34 12 1805 1811
38. Tsuta K., Tanabe Y., Yoshida A., et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol: 2011; 6 7 1190 1199
39. Turner B. M., Cagle P. T., Sainz I. M., Fukuoka J., Shen S. S., Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med: 2012; 136 2 163 171
40. Lindeman N. I., Cagle P. T., Beasley M. B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn: 2013; 15 4 415 453
41. Cagle P. T., Chirieac L. R. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med: 2012; 136 5 504 509
42. Cagle P. T., Allen T. C. Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med: 2012; 136 12 1482 1491
43. Maemondo M., Inoue A., Kobayashi K., et al. North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med: 2010; 362 25 2380 2388
44. Lynch T. J., Bell D. W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med: 2004; 350 21 2129 2139 (Pubitemid 38637993)
45. Mitsudomi T., Morita S., Yatabe Y., et al. West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol: 2010; 11 2 121 128
46. Mok T. S., Wu Y. L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med: 2009; 361 10 947 957
47. Paez J. G., Jänne P. A., Lee J. C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science: 2004; 304 5676 1497 1500 (Pubitemid 38720929)
48. Shaw A. T., Yeap B. Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol: 2009; 27 26 4247 4253
49. Gainor J. F., Varghese A. M., Ou S. H., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res: 2013; 19 15 4273 4281
50. Wong D. W., Leung E. L., So K. K., et al. University of Hong Kong Lung Cancer Study Group The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer: 2009; 115 8 1723 1733
51. Kwak E. L., Bang Y. J., Camidge D. R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med: 2010; 363 18 1693 1703
52. Shaw A. T., Kim D. W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med: 2013; 368 25 2385 2394
53. Acquaviva J., Wong R., Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta: 2009; 1795 1 37 52
54. Yoshida A., Kohno T., Tsuta K., et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol: 2013; 37 4 554 562
55. Bergethon K., Shaw A. T., Ou S. H., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol: 2012; 30 8 863 870
56. Bos M., Gardizi M., Schildhaus H. U., et al. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer: 2013; 81 1 142 143
57. Funai K., Yokose T., Ishii G., et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol: 2003; 27 7 978 984 (Pubitemid 36758901)
58. Moro-Sibilot D., Lantuejoul S., Diab S., et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J: 2008; 31 4 854 859
59. Zhang H., Liu J., Cagle P. T., Allen T. C., Laga A. C., Zander D. S. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol: 2005; 18 1 111 118 (Pubitemid 40128103)
60. Pelosi G., Fabbri A., Bianchi F., et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol: 2012; 7 2 281 290
61. Travis W. D. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol: 2012; 25 01 S18 S30
62. Bishop J. A., Ogawa T., Chang X., et al. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol: 2012; 36 1 142 148
63. Weiss J., Sos M. L., Seidel D., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med: 2010; 2 62 62ra93
64. Dutt A., Ramos A. H., Hammerman P. S., et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE: 2011; 6 6 e20351
65. Olaso E., Labrador J. P., Wang L., et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem: 2002; 277 5 3606 3613 (Pubitemid 34953233)
66. Hammerman P. S., Sos M. L., Ramos A. H., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov: 2011; 1 1 78 89
67. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med: 2010; 134 11 1628 1638
68. Swarts D. R., Ramaekers F. C., Speel E. J. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta: 2012; 1826 2 255 271
69. Gustafsson B. I., Kidd M., Modlin I. M. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol: 2008; 20 1 1 12 (Pubitemid 350190975)
70. Gustafsson B. I., Kidd M., Chan A., Malfertheiner M. V., Modlin I. M. Bronchopulmonary neuroendocrine tumors. Cancer: 2008; 113 1 5 21 (Pubitemid 351976381)
71. Powell J. M. Metastatic carcinoid of bone. Report of two cases and review of the literature. Clin Orthop Relat Res: 1988; 230 266 272
72. McCaughan B. C., Martini N., Bains M. S. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg: 1985; 89 1 8 17 (Pubitemid 16237652)
73. Pelosi G., Rodriguez J., Viale G., Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol: 2005; 29 2 179 187 (Pubitemid 40170635)
74. Lim E., Goldstraw P., Nicholson A. G., et al. Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007. J Thorac Oncol: 2008; 3 10 1194 1201
75. Travis W. D., Giroux D. J., Chansky K., et al. International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol: 2008; 3 11 1213 1223
76. Lin X., Saad R. S., Luckasevic T. M., Silverman J. F., Liu Y. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol: 2007; 15 4 407 414 (Pubitemid 350307846)
77. Sica G., Wagner P. L., Altorki N., et al. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med: 2008; 132 12 1889 1895
78. den Bakker M. A., Thunnissen F. B. Neuroendocrine tumours-challenges in the diagnosis and classification of pulmonary neuroendocrine tumours. J Clin Pathol: 2013; May 17. [Epub ahead of print]
79. Swarts D. R., Henfling M. E., Van Neste L., et al. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. Clin Cancer Res: 2013; 19 8 2197 2207
80. Marchevsky A. M., Gal A. A., Shah S., Koss M. N. Morphometry confirms the presence of considerable nuclear size overlap between small cells and large cells in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol: 2001; 116 4 466 472 (Pubitemid 34450278)
81. Vallières E., Shepherd F. A., Crowley J., et al. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol: 2009; 4 9 1049 1059
82. Lim E., Belcher E., Yap Y. K., Nicholson A. G., Goldstraw P. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol: 2008; 3 11 1267 1271
83. Waddell T. K., Shepherd F. A. Should aggressive surgery ever be part of the management of small cell lung cancer? Thorac Surg Clin: 2004; 14 2 271 281
84. Travis W. D., Gal A. A., Colby T. V., Klimstra D. S., Falk R., Koss M. N. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol: 1998; 29 3 272 279 (Pubitemid 28123925)
85. Iyoda A., Hiroshima K., Nakatani Y., Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg: 2007; 84 2 702 707
86. Weissferdt A., Moran C. A. Pulmonary salivary gland-type tumors with features of malignant mixed tumor (carcinoma ex pleomorphic adenoma): a clinicopathologic study of five cases. Am J Clin Pathol: 2011; 136 5 793 798
87. Moran C. A. Primary salivary gland-type tumors of the lung. Semin Diagn Pathol: 1995; 12 2 106 122
88. Molina J. R., Aubry M. C., Lewis J. E., et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer: 2007; 110 10 2253 2259 (Pubitemid 350100748)
89. Maygarden S. J., Detterbeck F. C., Funkhouser W. K. Bronchial margins in lung cancer resection specimens: utility of frozen section and gross evaluation. Mod Pathol: 2004; 17 9 1080 1086 (Pubitemid 39128234)
90. Heitmiller R. F., Mathisen D. J., Ferry J. A., Mark E. J., Grillo H. C. Mucoepidermoid lung tumors. Ann Thorac Surg: 1989; 47 3 394 399 (Pubitemid 19100469)
91. Yousem S. A., Hochholzer L. Mucoepidermoid tumors of the lung. Cancer: 1987; 60 6 1346 1352 (Pubitemid 17157843)
92. Kang D. Y., Yoon Y. S., Kim H. K., et al. Primary salivary gland-type lung cancer: surgical outcomes. Lung Cancer: 2011; 72 2 250 254
93. Achcar RdeO, Nikiforova M. N., Dacic S., Nicholson A. G., Yousem S. A. Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol: 2009; 40 6 854 860
94. Doganay L., Bilgi S., Ozdil A., Yoruk Y., Altaner S., Kutlu K. Epithelial-myoepithelial carcinoma of the lung. A case report and review of the literature. Arch Pathol Lab Med: 2003; 127 4 e177 e180
95. Nguyen C. V., Suster S., Moran C. A. Pulmonary epithelial-myoepithelial carcinoma: a clinicopathologic and immunohistochemical study of 5 cases. Hum Pathol: 2009; 40 3 366 373
96. Churg A., Colby T. V., Cagle P., et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol: 2000; 24 9 1183 1200
97. Bhardwaj R. Differentiation of malignant pleural mesothelioma from other pleural diseases. Thorax: 2012; 67 1 61
98. Hasteh F., Lin G. Y., Weidner N., Michael C. W. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol: 2010; 118 2 90 96
99. Butnor K. J., Sporn T. A., Ordonez N. G.; Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of pleural mesothelioma. Hum Pathol: 2007; 38 11 1587 1589
100. McCaughey W. T., Colby T. V., Battifora H., et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. Mod Pathol: 1991; 4 3 342 353
101. Miller B. H., Rosado-de-Christenson M. L., Mason A. C., Fleming M. V., White C. C., Krasna M. J. From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation. Radiographics: 1996; 16 3 613 644 (Pubitemid 126448688)
102. Kao S. C., Griggs K., Lee K., et al. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology: 2011; 43 4 313 317
103. Klebe S., Nurminen M., Leigh J., Henderson D. W. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology: 2009; 41 2 140 148
104. King J. E., Thatcher N., Pickering C. A., Hasleton P. S. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology: 2006; 48 3 223 232
105. Westfall D. E., Fan X., Marchevsky A. M. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn Cytopathol: 2010; 38 1 9 14
106. Yaziji H., Battifora H., Barry T. S., et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol: 2006; 19 4 514 523
107. Marchevsky A. M. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med: 2008; 132 3 397 401 (Pubitemid 351328814)
108. Sidhu G. S. The ultrastructure of malignant epithelial neoplasms of the lung. Pathol Annu: 1982; 17 Pt 1 235 266
109. Dardick I., Al-Jabi M., McCaughey W. T., Srigley J. R., van Nostrand A. W., Ritchie A. C. Ultrastructure of poorly differentiated diffuse epithelial mesotheliomas. Ultrastruct Pathol: 1984; 7 2-3 151 160 (Pubitemid 15075667)
110. Flieder D. B. Commonly encountered difficulties in pathologic staging of lung cancer. Arch Pathol Lab Med: 2007; 131 7 1016 1026 (Pubitemid 47057888)
111. Butnor K. J., Vollmer R. T., Blaszyk H., Glatz K. Interobserver agreement on what constitutes visceral pleural invasion by non-small cell lung carcinoma: an internet-based assessment of international current practices. Am J Clin Pathol: 2007; 128 4 638 647 (Pubitemid 47584443)
112. Marchevsky A. M. Problems in pathologic staging of lung cancer. Arch Pathol Lab Med: 2006; 130 3 292 302
113. Detterbeck F. C., Boffa D. J., Tanoue L. T. The new lung cancer staging system. Chest: 2009; 136 1 260 271
114. Dacic S. Dilemmas in lung cancer staging. Arch Pathol Lab Med: 2012; 136 10 1194 1197
115. Detterbeck F. C., Boffa D. J., Tanoue L. T., Wilson L. D. Details and difficulties regarding the new lung cancer staging system. Chest: 2010; 137 5 1172 1180
116. Kozower B. D., Larner J. M., Detterbeck F. C., Jones D. R. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest: 2013; 143 (5, Suppl): e369S e399S
117. Detterbeck F. C., Postmus P. E., Tanoue L. T. The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest: 2013; 143 (5, Suppl): e191S e210S